Lilly Expands Leadership Team for Growth

Leadership Appointments

Eli Lilly and Company announced the addition of Carole Ho and Adrienne Brown to its Executive Committee. Carole Ho will serve as Executive Vice President and President of Lilly Neuroscience, bringing over 20 years of biopharmaceutical experience. Adrienne Brown, previously Group Vice President of Corporate Business Development at Lilly, has been promoted to Executive Vice President and President of Lilly Immunology.

Expanded Roles

Daniel Skovronsky will take on an expanded role as Chief Scientific and Product Officer, overseeing research and development, global launches, and product strategy for Cardiometabolic Health, Immunology, and Neuroscience. Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, will also expand his role to include leadership of the corporate business development function.

Strategic Focus

The leadership changes are part of Lilly's strategy to accelerate its pipeline, create new portfolio opportunities, and enhance patient access to its medicines. The company aims to drive growth in neuroscience and immunology through these appointments and expanded roles.